ClinicalTrials.gg
CompletedNCT00700570Updated Nov 2, 2016Results posted

A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer

A Phase 2 interventional study of bevacizumab [Avastin] and capecitabine [Xeloda] in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 6 sites in Taiwan. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
Up to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.

Enrollment
99th of 183
45 · median 50
Started
2008
with 15 others
Phase 2
110 of 206
12 open now
Registered
112th of 206
by date
Lead sponsor
11 of 206
Hoffmann-La Roche

Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 99th largest by enrollment of the 183 interventional ones that give a count, is one of 16 that started in 2008, is one of 110 in phase 2, and was the 112th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: Up to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies testing oxaliplatin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with metastatic colorectal cancer with unresectable liver metastasis. Patients will receive Avastin 5mg/kg iv on day 1 of every 2 week cycle, oxaliplatin 85mg/m2 iv on day 1 of every 2 week cycle, and capecitabine 1000mg/m2 on days 1-5 and 8-12 of every 2 week cycle. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
Up to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, \<=75 years of age;
  • chemotherapy-naive for stage IV colorectal cancer with unresectable liver ;
  • >=1 ;
  • status 0-2.

Exclusion criteria

Exclusion Criteria:

  • prior exposure to Avastin;
  • clinical or radiological evidence of ;
  • uncontrolled hypertension, or cardiovascular disease;
  • ongoing treatment with aspirin (>325mg/day) or other medications known to predispose to gastrointestinal ulceration.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda] · Drug: oxaliplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases

    Participants were assessed via microscopic and macroscopic examination for tumor resectability after completion of 5 cycles of neoadjuvant treatment. Unresectable participants exhibited any of the following criteria: greater than or equal to (≥) 4 liver metastases; location and/or distribution of metastatic disease within the liver considered unsuitable for resection with clear margins; liver involvement precluding resection, in the setting of adequate parenchymal volume for otherwise viable liver function in the immediate postoperative period; and inability to maintain adequate circulation for viable liver function. Participants who had not met any of the above criteria at the end of 5 cycles underwent surgical resection. The percentage of participants with conversion from initially unresectable to resectable liver metastases was calculated as \[number of participants eligible for surgical resection divided by the number analyzed\] multiplied by 100.

    Time frame: After 5 cycles of neoadjuvant treatment (10 weeks)

Secondary outcomes

  1. Percentage of Participants With Disease Progression

    Objective tumor response was assessed using RECIST version 1.1. Disease progression was defined as a ≥20 percent (%) increase in the sum of longest diameters of target lesions, taking as reference the smallest sum obtained at previous tumor assessment, or the appearance of any new lesions. The percentage of participants with disease progression was calculated as \[number of participants meeting the above criteria divided by the number analyzed\] multiplied by 100.

    Time frame: Up to approximately 3 years (at Baseline, end of Cycle 5, time of surgery, and within 4 weeks of end of treatment [EOT])

  2. Time to Disease Progression

    Objective tumor response was assessed using RECIST version 1.1. Disease progression was defined as a ≥20% increase in the sum of longest diameters of target lesions, taking as reference the smallest sum obtained at previous tumor assessment, or the appearance of any new lesions. Time to disease progression was defined as the time from first dose to time of disease progression. Participants without progression were censored at the time of last tumor assessment. Time to disease progression was estimated using Kaplan-Meier analysis and expressed in months.

    Time frame: Up to approximately 3 years (at Baseline, end of Cycle 5, time of surgery, and within 4 weeks of EOT)

  3. Percentage of Participants With a Best Overall Tumor Response of Complete Response (CR) or PR According to RECIST Version 1.1

    Objective tumor response was assessed using RECIST version 1.1. CR was defined as the disappearance of all target lesions, and PR was defined as a ≥30% decrease in the sum of longest diameters compared to Baseline. Response was confirmed at a minimum of 4 weeks after the first documented response. The percentage of participants with confirmed CR or PR was calculated as \[number of participants meeting the respective criteria divided by the number analyzed\] multiplied by 100.

    Time frame: Up to approximately 3 years (at Baseline, end of Cycle 5, time of surgery, within 4 weeks of EOT, and at least 4 weeks after initial response)

  4. Percentage of Participants by Best Overall Tumor Response According to RECIST Version 1.1

    Objective tumor response was assessed using RECIST version 1.1. CR was defined as the disappearance of all target lesions, and PR was defined as a ≥30% decrease in the sum of longest diameters compared to Baseline. Response was to be confirmed at a minimum of 4 weeks after the first documented response. Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, as well as no new target lesions. Disease progression or PD was defined as a ≥20% increase in the sum of longest diameters of target lesions, taking as reference the smallest sum obtained at previous tumor assessment, or the appearance of any new lesions. Non-evaluability for tumor assessment was also documented when applicable. The percentage of participants with each level of response was calculated as \[number of participants meeting the respective criteria divided by the number analyzed\] multiplied by 100.

    Time frame: Up to approximately 3 years (at Baseline, end of Cycle 5, time of surgery, within 4 weeks of EOT, and at least 4 weeks after initial response)

07

Results

Posted Oct 1, 2015

Participant flow

Participant flow — Overall Study
MilestoneResectedUnresected
Started1926
Completed80
Not completed1126
Withdrew: Adverse event26
Withdrew: Discretion of investigator or sponsor03
Withdrew: Disease progression811
Withdrew: Withdrawal by subject16

Outcome measures

PrimaryPercentage of Participants With Conversion From Unresectable to Resectable Liver Metastases

Participants were assessed via microscopic and macroscopic examination for tumor resectability after completion of 5 cycles of neoadjuvant treatment. Unresectable participants exhibited any of the following criteria: greater than or equal to (≥) 4 liver metastases; location and/or distribution of metastatic disease within the liver considered unsuitable for resection with clear margins; liver involvement precluding resection, in the setting of adequate parenchymal volume for otherwise viable liver function in the immediate postoperative period; and inability to maintain adequate circulation for viable liver function. Participants who had not met any of the above criteria at the end of 5 cycles underwent surgical resection. The percentage of participants with conversion from initially unresectable to resectable liver metastases was calculated as \[number of participants eligible for surgical resection divided by the number analyzed\] multiplied by 100.

Time frame:
After 5 cycles of neoadjuvant treatment (10 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases
percentage of participantsAll Participants
Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases42.2
SecondaryPercentage of Participants With Disease Progression

Objective tumor response was assessed using RECIST version 1.1. Disease progression was defined as a ≥20 percent (%) increase in the sum of longest diameters of target lesions, taking as reference the smallest sum obtained at previous tumor assessment, or the appearance of any new lesions. The percentage of participants with disease progression was calculated as \[number of participants meeting the above criteria divided by the number analyzed\] multiplied by 100.

Time frame:
Up to approximately 3 years (at Baseline, end of Cycle 5, time of surgery, and within 4 weeks of end of treatment [EOT])
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression
percentage of participantsResectedUnresected
Percentage of Participants With Disease Progression52.646.2
SecondaryTime to Disease Progression

Objective tumor response was assessed using RECIST version 1.1. Disease progression was defined as a ≥20% increase in the sum of longest diameters of target lesions, taking as reference the smallest sum obtained at previous tumor assessment, or the appearance of any new lesions. Time to disease progression was defined as the time from first dose to time of disease progression. Participants without progression were censored at the time of last tumor assessment. Time to disease progression was estimated using Kaplan-Meier analysis and expressed in months.

Time frame:
Up to approximately 3 years (at Baseline, end of Cycle 5, time of surgery, and within 4 weeks of EOT)
Reported as:
Median · months
Time to Disease Progression
monthsResectedUnresected
Time to Disease Progression10.1 (7.0 to 20.4)8.7 (5.0 to 14.2)
Statistical analysis
  • Resected vs Unresected · Log Rank · p = 0.1341
SecondaryPercentage of Participants With a Best Overall Tumor Response of Complete Response (CR) or PR According to RECIST Version 1.1

Objective tumor response was assessed using RECIST version 1.1. CR was defined as the disappearance of all target lesions, and PR was defined as a ≥30% decrease in the sum of longest diameters compared to Baseline. Response was confirmed at a minimum of 4 weeks after the first documented response. The percentage of participants with confirmed CR or PR was calculated as \[number of participants meeting the respective criteria divided by the number analyzed\] multiplied by 100.

Time frame:
Up to approximately 3 years (at Baseline, end of Cycle 5, time of surgery, within 4 weeks of EOT, and at least 4 weeks after initial response)
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Tumor Response of Complete Response (CR) or PR According to RECIST Version 1.1
percentage of participantsResectedUnresected
Percentage of Participants With a Best Overall Tumor Response of Complete Response (CR) or PR According to RECIST Version 1.147.434.6
SecondaryPercentage of Participants by Best Overall Tumor Response According to RECIST Version 1.1

Objective tumor response was assessed using RECIST version 1.1. CR was defined as the disappearance of all target lesions, and PR was defined as a ≥30% decrease in the sum of longest diameters compared to Baseline. Response was to be confirmed at a minimum of 4 weeks after the first documented response. Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, as well as no new target lesions. Disease progression or PD was defined as a ≥20% increase in the sum of longest diameters of target lesions, taking as reference the smallest sum obtained at previous tumor assessment, or the appearance of any new lesions. Non-evaluability for tumor assessment was also documented when applicable. The percentage of participants with each level of response was calculated as \[number of participants meeting the respective criteria divided by the number analyzed\] multiplied by 100.

Time frame:
Up to approximately 3 years (at Baseline, end of Cycle 5, time of surgery, within 4 weeks of EOT, and at least 4 weeks after initial response)
Reported as:
Number · percentage of participants
Percentage of Participants by Best Overall Tumor Response According to RECIST Version 1.1
percentage of participantsResectedUnresected
CR36.80
PR10.534.6
SD015.4
PD52.646.2
Non-evaluable03.8
Statistical analysis
  • Resected vs Unresected · Fisher Exact · p = 0.0010

Adverse events

Collected over Up to approximately 3 years (continuously until 4 weeks after EOT). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants—11/45 (24.4%)45/45 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventAll Participants
DiarrhoeaGastrointestinal disorders3/45
IleusGastrointestinal disorders2/45
PyrexiaGeneral disorders2/45
EnteritisGastrointestinal disorders1/45
Gastrointestinal haemorrhageGastrointestinal disorders1/45
Enterocolitis infectiousInfections and infestations1/45
Perihepatic abscessInfections and infestations1/45
Intestinal anastomosis complicationInjury, poisoning and procedural complications1/45
HypoglycaemiaMetabolism and nutrition disorders1/45
Tumour associated feverNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/45
Most frequent other events
Showing 10 of 29
Most frequent other events
EventAll Participants
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders35/45
Decreased appetiteMetabolism and nutrition disorders20/45
ThrombocytopeniaBlood and lymphatic system disorders19/45
Neuropathy peripheralNervous system disorders19/45
FatigueGeneral disorders18/45
VomitingGastrointestinal disorders17/45
DiarrhoeaGastrointestinal disorders16/45
ProteinuriaRenal and urinary disorders15/45
NauseaGastrointestinal disorders14/45
NeutropeniaBlood and lymphatic system disorders11/45

Baseline characteristics

Intent-to-Treat (ITT) Population: All enrolled participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)ResectedUnresectedTotal
Mean55.0 ± 11.655.1 ± 10.455.08 ± 11.2
Gender
Gender(Participants)ResectedUnresectedTotal
Female61218
Male131427
08

Study locations

6 sites
  • Kaohsiung, 00833, Taiwan
  • Kaohsiung, 807, Taiwan
  • Taichung, 407, Taiwan
  • Taipei, 00112, Taiwan
  • Taipei, 112, Taiwan
  • Taoyuan County, 333, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2008
First posted
Jun 18, 2008
Start
Aug 2008
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Oct 1, 2015
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00700570
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 18, 2008
Start date
Aug 2008
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Oct 1, 2015
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxaliplatin

Start the discussion